CAS: 93957-55-2; Rel-(3S,5R,E)-7-(3-(4-Fluorophenyl)-1-Isopropyl-1H-Indol-2-yl)-3,5-Dihydroxyhept-6-Enoic Acid, Sodium Salt

专利信息

专利号:WO-2006048893-A3
优先权日:2004-11-05
标 题:A process for synthesis of large particle size statin compounds
发明人：SURI SANJAY; SARIN GURDEEP SINGH
权利人:MOREPEN LAB LTD; SURI SANJAY; SARIN GURDEEP SINGH
摘要:This invention discloses a process for synthesis of with large size statin compounds comprising adding solution of desired statin compound either crystalline or amorphous form, optionally obtained from, their intermediates by known methods, in organic solvent to anti-solvent, under stirring, optionally the solvent was being evaporated, isolating the title compound by centrifugation followed by drying under vacuum. Specifically the process was directed to the synthesis of Atorvastatin calcium and Fluvastatin Sodium.

专利号:US-8269001-B2
优先权日:2005-10-05
标题 :Process for the synthesis of HMG-CoA reductase inhibitors
发明人：CASAR ZDENKO
权利人:CASAR ZDENKO; LEK PHARMACEUTICALS
摘要:A novel synthesis of statins uses Wittig reaction of a heterocyclic core of statin with a lactonized side chain already possessing needed stereochemistry. Any separation of diastereoisomers is performed early in the course of synthesis.

专利号:US-10022366-B2
优先权日:2013-04-23
标 题:Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery
发明人：STINCHCOMB AUDRA L; GHOSH PRIYANKA
权利人:STINCHCOMB AUDRA L; GHOSH PRIYANKA; UNIV MARYLAND; UNIV KENTUCKY RES FOUND
摘要:Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU) was used to enhance pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin.

专利号:WO-2006021326-A1
优先权日:2004-08-27
标题:Process and intermediates for the selective synthesis of fluvastatin
发明人：ZHU GUORONG; GONG HONGQUAN; BECKER STEFAN
权利人:ZHEJIANG HISUN PHARMACEUTICAL; TIEFENBACHER PHARMACHEMIKALIEN; ZHU GUORONG; GONG HONGQUAN; BECKER STEFAN
摘要:The invention relates to process for the selective preparation of 3-hydroxy-6-dialkoxyphosphoryl-5-oxo-hexanoic acid esters, comprising a first step, in which a methylphosphonic acid dialkylester is treated with a base, and a second step, in which the product of the primary reaction is reacted with an optionally 3-protected 3-hydroxy-1,5-pentanoic diacid ester.

专利号:US-7851624-B2
优先权日:2003-12-24
标题 :Triol form of rosuvastatin and synthesis of rosuvastatin
发明人：NIDDAM-HILDESHEIM VALERIE; BALANOV ANNA; VEINBERG IRENA
权利人:TEVA PHARAMACEUTICAL IND LTD
摘要:Provided is a rosuvastatin triol and its use as a reference standard for analysis of rosuvastatin. Also provided are methods for preparation of rosuvastatin.

专利号:US-8158362-B2
优先权日:2005-03-30
标题:Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
发明人：HELGADOTTIR ANNA; HAKONARSON HAKON; GULCHER JEFFREY R; GURNEY MARK E
权利人:HELGADOTTIR ANNA; HAKONARSON HAKON; GULCHER JEFFREY R; GURNEY MARK E; DECODE GENETICS EHF
摘要:Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.